Document is current
Any future updates will be listed below
-
Authors
Thunold, Solfrid https://orcid.org/0009-0004-9277-7796
Hernes, Eivor
Farooqi, Saima
Öjlert, Åsa Kristina
Francis, Roslyn J.
Nowak, Anna K.
Szejniuk, Weronika Maria
Nielsen, Søren Steen
Cedres, Susana
Perdigo, Marc Simo
Sørensen, Jens Benn
Meltzer, Carin
Mikalsen, Lars Tore Gyland
Helland, Åslaug
Malinen, Eirik
Haakensen, Vilde Drageset
-
Funding
Funding for this research was provided by:
Helse Sør-Øst RHF (2020077, 2021083)
- License Information
-
More Information
Article History
Received: 7 February 2024
Accepted: 16 July 2024
First Online: 12 August 2024
Declarations
:
: The trial was approved by the regional ethics committee (20/47804) and each site ethics committee and was conducted in accordance with the Declaration of Helsinki of the World Medical Association and ICH E6 for Good Clinical Practice.
: All patients provided written informed consent.
: The authors affirm that human research participants provided informed consent for publication of the images in Figures , , .
: ST - External speaker BMSWMS – no conflict of interestEH – no conflicts of interestJBS - BMS Advisory BoardÅH - Advisory/consultancy/meeting presentation roles for AbbVie, AstraZeneca, BMS, Pfizer, Roche, Janssen, MSD, Sanofi, Bayer, Medicover, and Takeda with honoraria directed to own institution, and receiving research grants from Roche, BMS, Ultimovacs, AstraZeneca, Novartis, InCyte, Eli Lilly, Illumina, Merck, Nanopore, GlaxoSmithKline.AKN – Astra Zeneca DSMB; Research funding to institution from Astra Zeneca.ÅKÖ - no disclosures.VDH: Advisory boards: Astra Zeneca, Novartis, Lectures/text: Astra Zeneca, Pfizer, Janssen, BMS, TakedaEM – no conflictsCM – no conflict of interestLTM: No conflicts of interestRF – advisory/consultancy for AIQ SolutionsRF – advisory/consultancy for AIQ SolutionsSSN-no conflict of interestSF - Advisory/consultancy/meeting presentation MSD, Astra Zeneca, PfizerMS – no disclosures
